
### 28th September 2016

## Hella

Automotive

### Price EUR35.79

Bloomberg				HLE GR		
•				HLE.DE		
	Reuters 12-month High / Low (EUR)					
•	39.3 / 27.7 3,977					
	Market Cap (EURm) Ev (BG Estimates) (EURm)					
			4,001 137.0			
3y EPS CAGR	Avg. 6m daily volume (000)					
SY LFS CAUK		17.5%				
	1 M	3 M	6 M 33	1/12/15		
Absolute perf.	-0.9%	25.2%	-2.0%	-7.1%		
Auto & Parts	-1.9%	13.6%	-3.8%	-16.1%		
DJ Stoxx 600	-1.0%	10.2%	1.5%	-7.0%		
YEnd May (EURm)	05/16	05/17e	05/18e	05/19e		
Sales	6,352	6,611	6,940	7,288		
% change		4.1%	5.0%	5.0%		
EBITDA	816	875	944	1,037		
EBIT	366.5	446.7	479.6	538.3		
% change		21.9%	7.4%	12.2%		
Net income	268.5	355.7	385.6	436.1		
% change		32.5%	8.4%	13.1%		
	05/16	05/17e	05/18e	05/19e		
Operating margin	5.8	6.8	6.9	7.4		
Net margin	4.2	5.4	5.6	6.0		
Net margin ROE	4.2 13.6	5.4 15.9	5.6 15.3	6.0 15.3		
•						
ROE	13.6	15.9	15.3	15.3		
ROE ROCE	13.6 8.5	15.9 9.6	15.3 9.8	15.3 10.4		
ROE ROCE Gearing	13.6 8.5 28.6	15.9 9.6 23.0	15.3 9.8 17.4	15.3 10.4 11.5		
ROE ROCE Gearing (EUR)	13.6 8.5 28.6 05/16	15.9 9.6 23.0 05/17e	15.3 9.8 17.4 05/18e	15.3 10.4 11.5 05/19e		
ROE ROCE Gearing (EUR) EPS	13.6 8.5 28.6 05/16 2.42	15.9 9.6 23.0 <b>05/17e</b> 3.20	15.3 9.8 17.4 <b>05/18e</b> 3.47	15.3 10.4 11.5 <b>05/19</b> e 3.93		
ROE ROCE Gearing (EUR) EPS % change	13.6 8.5 28.6 05/16 2.42	15.9 9.6 23.0 <b>05/17e</b> 3.20 <i>32.5%</i>	15.3 9.8 17.4 <b>05/18e</b> 3.47 <i>8.4%</i>	15.3 10.4 11.5 <b>05/19e</b> 3.93 <i>13.1%</i>		
ROE ROCE Gearing (EUR) EPS % change P/E	13.6 8.5 28.6 05/16 2.42 - 14.8x	15.9 9.6 23.0 <b>05/17e</b> 3.20 <i>32.5%</i> 11.2x	15.3 9.8 17.4 <b>05/18e</b> 3.47 <i>8.4%</i> 10.3x	15.3 10.4 11.5 <b>05/19e</b> 3.93 <i>13.1%</i> 9.1x		
ROE ROCE Gearing (EUR) EPS % change P/E FCF yield (%)	13.6 8.5 28.6 05/16 2.42 - 14.8x 1.0%	15.9 9.6 23.0 05/17e 3.20 32.5% 11.2x 3.3%	15.3 9.8 17.4 <b>05/18e</b> 3.47 <i>8.4%</i> 10.3x 4.6%	15.3 10.4 11.5 <b>05/19e</b> 3.93 <i>13.1%</i> 9.1x 5.7%		
ROE ROCE Gearing (EUR) EPS % change P/E FCF yield (%) Dividends (EUR)	13.6 8.5 28.6 05/16 2.42 - 14.8x 1.0% 0.77	15.9 9.6 23.0 <b>05/17e</b> 3.20 <i>32.5%</i> 11.2x 3.3% 0.96	15.3 9.8 17.4 <b>05/18e</b> 3.47 8.4% 10.3x 4.6% 1.04	15.3 10.4 11.5 <b>05/19e</b> 3.93 <i>13.1%</i> 9.1x 5.7% 1.18		
ROE ROCE Gearing (EUR) EPS % change P/E FCF yield (%) Dividends (EUR) Div yield (%)	13.6 8.5 28.6 05/16 2.42 - 14.8x 1.0% 0.77 2.2%	15.9 9.6 23.0 05/17e 3.20 32.5% 11.2x 3.3% 0.96 2.7%	15.3 9.8 17.4 <b>05/18e</b> 3.47 8.4% 10.3x 4.6% 1.04 2.9%	15.3 10.4 11.5 <b>05/19e</b> 3.93 <i>13.1%</i> 9.1x 5.7% 1.18 3.3%		



### Q1-2016/17 fist take: a solid year start despite unfavourable FX effect

Fair Value EUR45 (+26%)

Hella posted this morning solid Q1-2016/17 earnings this morning, despite unfavourable FX and disposal effects. All earnings metrics came out slightly above our expectations, with adjusted EBIT margin up 80bp to 7.6% (BG @ 7.2%). Full year objectives were reiterated with the group confirming both its market outlook for 2016 (+3% growth) and its internal sales and margin targets. We expect positive share price reaction this morning especially after the recent share price drop observed over past five days. Buy, FV @ EUR45.

BUY

### ANALYSIS

- Main Q1-16/17 figures: Total sales for first guarter are up 3.8% YoY to EUR1.55bn, and up 5.2% LfL when adjusted from FX and disposal effects. Automotive segment revenues are up 3.2% to EUR1.16bn while sales from Aftermarket grew by 7.3% to EUR313m due to positive wholese and strong workshop development. The growth in auto segment was driven particularly by innovative LED solutions and energy management products. Despite a 60bp rise in R&D expenses ratio (to 9.9%) due to strong investments in new product generations in lighting and electrocnics, group's adjusted EBIT is strongly up, as expected, by 17% to EUR117m, above BG and market expectations (respectively EUR109m & EUR114m), allowing Hella to improve its adjusted EBIT margin from 6.8% to 7.6%. As a reminder the group is benefiting over first quarter from positive base effect as last year margin in the Automotive segment was affected by the failure of a Chinese supplier that had caused high one-time expenses. On a LfL basis the group's adjusted EBIT then grew by 17% to EUR118m (BG @ EUR112m) helped by improved earnings contribution from the JVs. Net Q1-16/17 earnings came out at EUR83m, and more than doubled compared with last year, slightly above our expectations (BG @ EUR76.6m). As anticipated group's adjusted operative CF decreased compared with last year, due to payment of trade liabilities after build-up at year-end. Net capex spent remained stable though, at EUR106m.
- Elements to retain from this publication: 1/Earnings are strongly up compared with last year on a YoY basis, helped by favourable base comparison, 2/Even adjusted from this, group's adjusted EBIT is up 17% while group's net profit is up >29% thanks to positive sales growth coming from both Automotive segment (+3.2%) and Aftermarket segment (+7.3%) despite unfavourable FX effect. 3/R&D expenses continued to surge, yet this effect was more than offset by gross margin improvement (higher capacity utilization) and by lower SG&A expenses ratio allowing the group to generate higher profitability. 4/Market assumptions for 2016 & for 2017 were reiterated despite more cautious comment on U.S. and on China. We hope to get more details during the conference call this afternoon given the uncertainties linked to these two markets for 2017.
- Conclusions: 2016/17 guidance was confirmed by the group. Hella still expects sales and adjusted EBIT to grow in the middle single-digit % range and the adjusted EBIT margin to be in line with 2015/16 (around 7.5%). We expect positive share price reaction this morning especially after the recent share price drop observed over past five days. Buy, FV @ EUR45

### VALUATION

- At current share price Hella is trading at 9.0x its 2017e EBIT and 11.2x its 2017e EPS
- Buy, FV @ EUR45

### NEXT CATALYSTS

• Conference call @ 01.30pm CEST time

Click here to download document



Analyst : Xavier Caroen 33(0) 1.56.68.75.18 xcaroen@bryangarnier.com Sector Team : Pierre-Antoine Chazal

## Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

### Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a			
DUI	recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of			
	elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock			
	feature an introduction outlining the key reasons behind the opinion.			

- NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
- SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

### Distribution of stock ratings

BUY ratings 55,8%

NEUTRAL ratings 32,5%

SELL ratings 11,7%

# Research Disclosure Legend

1	Bryan Garnier shareholding Bryan Garnier & Co Limited or another company in its group (together, the "Bryan Garnier Group") has a shareholding that, individually or combined, exceeds 5% of the paid up and issued share capital of a company that is the subject of this Report (the "Issuer").		No
2	Issuer shareholding in Bryan Garnier		
3	Financial interest	A member of the Bryan Garnier Group holds one or more financial interests in relation to the Issuer which are significant in relation to this report	No
4	Market maker or liquidity provider	A member of the Bryan Garnier Group is a market maker or liquidity provider in the securities of the Issuer or in any related derivatives.	No
5	Lead/co-lead manager	In the past twelve months, a member of the Bryan Garnier Group has been lead manager or co-lead manager of one or more publicly disclosed offers of securities of the Issuer or in any related derivatives.	No
6	Investment banking agreement	A member of the Bryan Garnier Group is or has in the past twelve months been party to an agreement with the Issuer relating to the provision of investment banking services, or has in that period received payment or been promised payment in respect of such services.	No
7	Research agreement	A member of the Bryan Garnier Group is party to an agreement with the Issuer relating to the production of this Report.	No
8	Analyst receipt or purchase of shares in Issuer	The investment analyst or another person involved in the preparation of this Report has received or purchased shares of the Issuer prior to a public offering of those shares.	No
9	Remuneration of analyst	The remuneration of the investment analyst or other persons involved in the preparation of this Report is tied to investment banking transactions performed by the Bryan Garnier Group.	No
10	Corporate finance client	In the past twelve months a member of the Bryan Garnier Group has been remunerated for providing corporate finance services to the issuer or may expect to receive or intend to seek remuneration for corporate finance services from the Issuer in the next six months.	No
11	Analyst has short position	The investment analyst or another person involved in the preparation of this Report has a short position in the securities or derivatives of the Issuer.	No
12	Analyst has long position	The investment analyst or another person involved in the preparation of this Report has a long position in the securities or derivatives of the Issuer.	No
13	Bryan Garnier executive is an officer	A partner, director, officer, employee or agent of the Bryan Garnier Group, or a member of such person's household, is a partner, director, officer or an employee of, or adviser to, the Issuer or one of its parents or subsidiaries. The name of such person or persons is disclosed above.	No
14	Analyst disclosure	The analyst hereby certifies that neither the views expressed in the research, nor the timing of the publication of the research has been influenced by any knowledge of clients positions and that the views expressed in the report accurately reflect his/her personal views about the investment and issuer to which the report relates and that no part of his/her remuneration was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in the report.	Yes
15	Other disclosures	Other specific disclosures: Report sent to Issuer to verify factual accuracy (with the recommendation/rating, price target/spread and summary of conclusions removed).	No

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

## BRYAN, GARNIER & CO

London	Paris	New York	Munich	New Delhi	
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	Widenmayerstrasse 29	The Imperial Hotel Janpath New Delhi 110 001 Tel +91 11 4132 6062	
15 St. Botolph Street	75008 Paris	New York, NY 10022	80538 Munich		
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Germany	+91 98 1111 5119	
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	+49 89 2422 62 11	Fax +91 11 2621 9062	
Fax: +44 (0) 207 332 2559	Regulated by the	FINRA and SIPC member		Geneva	
Authorised and regulated by the	Financial Conduct Authority (FCA) and the			rue de Grenus 7	
Financial Conduct Authority (FCA)	Autorité de Contrôle prudential et de			CP 2113 Genève 1, CH 1211	
	resolution (ACPR)			Tel +4122 731 3263	
				Fax+4122731 3243	

#### Important information

This document is classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Regulated by the FINMA

This report is prepared by Bryan Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited and should not rely on it for any purposes whatsoever.

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not

aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available..

### BRYAN, GARNIER & CO